Axcella Health (AXLA) Received its Third Buy in a Row
03 August 2022 - 10:07PM
TipRanks
After Chardan Capital and Wedbush gave Axcella Health (NASDAQ:
AXLA) a Buy rating last month, the company received another Buy,
this time from Noble Financial. Analyst Robert LeBoyer reiterated a
Buy rating on Axcella Health today and set a price target of $9.00.
The company's shares closed last Tuesday at $2.03. According to
TipRanks.com, LeBoyer is a 4-star analyst with an average return of
9.7% and a 35.9% success rate. LeBoyer covers the Healthcare
sector, focusing on stocks such as Lineage Cell Therapeutics,
Onconova Therapeutics, and Ayala Pharmaceuticals. The word on The
Street in general, suggests a Strong Buy analyst consensus rating
for Axcella Health with a $10.
https://www.tipranks.com/news/blurbs/axcella-health-axla-received-its-third-buy-in-a-row-4?utm_source=advfn.com&utm_medium=referral
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Oct 2023 to Nov 2023
Axcella Health (NASDAQ:AXLA)
Historical Stock Chart
From Nov 2022 to Nov 2023
